To investigate the development of HLA-DR-associated autoimmune diseases, we generated transgenic (Tg) mice with HLA-DRA-IEcx and HLA-DRBI*0401-IE[3 chimeric genes. The transgene-encoded proteins consisted of antigen-binding domains from HLA-DRA and HLA-DRBI*0401 molecules and the remaining domains from the IEd-ot and IEd-[3 chains. The chimeric molecules showed the same antigen-binding specificity as HLA-DRBI*0401 molecules, and were functional in presenting antigens to T cells. The Tg mice were backcrossed to MHC class II-deficient (IAl3-,IEoe-) mice to eliminate any effect of endogenous MHC class II genes on the development of autoimmune diseases. As expected, IA~x[3 or IEot[3 molecules were not expressed in Tg mice. Moreover, cell-surface expression of endogenous IE[3 associated with HLA-DRA-IEci was not detectable in several Tg mouse lines by flow cytometric analysis. The HLA-DRA-IEo~/HLA-DRBI*0401-IE[3 molecules rescued the development ofCD4 + T cells in MHC class II-deficient mice, but T cells expressing VI35, V1311, and VI312 were specifically deleted.
Summary
To investigate the development of HLA-DR-associated autoimmune diseases, we generated transgenic (Tg) mice with HLA-DRA-IEcx and HLA-DRBI*0401-IE[3 chimeric genes. The transgene-encoded proteins consisted of antigen-binding domains from HLA-DRA and HLA-DRBI*0401 molecules and the remaining domains from the IEd-ot and IEd-[3 chains. The chimeric molecules showed the same antigen-binding specificity as HLA-DRBI*0401 molecules, and were functional in presenting antigens to T cells. The Tg mice were backcrossed to MHC class II-deficient (IAl3-,IEoe-) mice to eliminate any effect of endogenous MHC class II genes on the development of autoimmune diseases. As expected, IA~x [3 or IEot[3 molecules were not expressed in Tg mice. Moreover, cell-surface expression of endogenous IE[3 associated with HLA-DRA-IEci was not detectable in several Tg mouse lines by flow cytometric analysis. The HLA-DRA-IEo~/HLA-DRBI*0401-IE[3 molecules rescued the development ofCD4 + T cells in MHC class II-deficient mice, but T cells expressing VI35, V1311, and VI312 were specifically deleted.
Tg mice were immunized with peptides, myelin basic protein (MBP) 87-106 and proteolipid protein (PLP) [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] , that are considered to be immunodominant epitopes in HLA-DR4 individuals. PLP175-192 provoked a strong proliferative response of lymph node T cells from Tg mice, and caused inflammatory lesions in white matter of the CNS and symptoms of experimental allergic encephalomyelitis (EAE). Immunization with MBP87-106 elicited a very weak proliferative T cell response and caused mild EAE. Non-Tg mice immunized with either PLP175-192 or MBP87-106 did not develop EAE. These results demonstrated that a human MHC class II binding site alone can confer susceptibility to an experimentally induced murine autoimmune disease.
S
ince HLA-DR4 allele is associated with the development of autoimmune diseases such as rheumatoid arthritis (RA) 1 and multiple sclerosis (MS), HLA-DR4/ human CD4 Tg mice and HLA-DR.4-IE Tg mice have been generated to investigate these diseases. These Tg mice are functional in activation of HLA-DR4-restricted T cells (1, 2) . However, since the Tg mice express both HLA-DR and endogenous mouse MHC class II molecules, both 1Abbreviations used in this paper: EAE, experimental allergic encephalomyelitis; HA, Flu virus hemagglutinin; MBP, myelin basic protein; MMTV, mouse mammary tumor virus; MS, multiple sclerosis; PLP, proteolipid protein; RA, rheumatoid arthritis; Tg, transgenic.
HLA-DR-and mouse MHC class II-restricted T cells are activated in response to antigens. Thus, the effect of HLA-DR on immune response and susceptibility to autoimmune disease is difficult to separate from that of the wild-type murine MHC class II molecules. In the present study, we produced HLA-DRA-IEcx/HLA-DRBI*0401-IE[3 Tg mice, and backcrossed them to MHC class II-deficient mice to eliminate any effect of endogenous MHC class II proteins. P~ecendy, the same strategy has been applied to HLA-DQ8 Tg mice (3) .
MBP and PLP are putative autoantigens involved in the pathogenesis of MS and can induce EAE in mice and rats (4) (5) (6) . Disease in these animal models can also be induced by adoptive transfer of MBP-or PLP-reactive T cells into syngeneic recipients (7) . In humans, MBP-or PLP-reactive HLA-DR-restricted T cells have been isolated from both MS patients and healthy controls (8) (9) (10) (11) (12) (13) . MBP-specific T cells in MS patients were activated while those from controls were in a resting state (13) . Activated MBP-and PLP-reactive T cells might therefore be i/avolved in the pathogenesis of MS. We show here that immunization of HLA-DRAIEc~/HLA-DRBI*0401-IE[3 Tg mice with PLP175-192 or MBP87-106 peptides induces the development of EAE.
Materials and Methods
Gene Constructs of HLA-DRA-IE~ol and HLA-DRBI*O401-IEar The DNA carrying exon 2 of HLA-DRA was amplified from pPR541 cosmid DNA (14) with primers, 5' ACAGAA-GGTGTCAGGTAGACTTGAAA3' and 5' GAGCACAGTTAC-CTCTGGAGGTAC3' by polymerase chain reaction (PCR) using Pfu DNA polymerase. The amplicon carrying the HLA-DRA exon 2 was treated with T4 DNA polymerase and subcloned into the Sinai site of pBluescript vector (Stratagene, San Diego, CA). An 8-kb BglI fragment of IEda gene derived from no. 32.1 IEdoI cosmid DNA (15) was also treated with T4 DNA polymerase and subcloned into the Smal site of pBluescript vector. The IEdct genomic DNA, from which exon 2 was removed by BstEII and BgllI digestion, was treated with Klenow Fragment ofDNA polymerase I. This DNA was then ligated to the 1.5-kb DNA fragment carrying HLA-DRA exon 2 that was digested from pBluescript vector with EcoRV and Bspl06 and then treated with Klenow Fragment ofDNA polymerase I.
A 7-kb EcoRI/KpnI DNA fragment carrying IEa[~ exon 1 was ligated to a 10-kb EcoRI/KpnI DNA fragment carrying IEal3 exon 3-6 (16). The ligated DNA was subcloned into the KpnI site ofpBluescript vector. The DNA fragment containing Exon 2 of HLA-DRBI*0401 was amplified from genomic DNA of Priess cells by PCR using Taq polymerase and primers, 5' TGA-AAGCGGTGCGTGCTGTTTAA3' and 5' CCCCATACATTT-CCCTTCCTTG3'. It was then subcloned into a pCRII vector (Invitrogen, San Diego, CA). The 0.85-kb EcoRI DNA fragment carrying exon 2 of HLA-DRBI*0401 was ligated to the EcoRI site of the IEdl3 genomic DNA which lacks exon 2.
Transgenic Mice. The gene constructs were removed from plasmid by digestion with Not I and Bspl06 for HLA-DRA-IEder and KpnI for HLA-DRBI*0401-IE[3. They were coinjected into C57BL/6 fertilized eggs. Tg mice were backcrossed to C2D (IA[3-,IEet-) mice on the C57BL/6 genetic background. Tg founders were first identified by PCR with 5' GGGAAGCAGGGG-GACTATGAC3' and 5' TTAGGGCAATGACTTCGTAGG3' primers for HLA-DRA-IEot and 5' TGAAAGCGGTGCGTG-CTGTTTAA3' and 5' CACCCGCTCCGTCCCGTTGAA3' primers for HLA-DPd31*0401-IE~, and were then confirmed by southern blot analysis using probes derived from exon 2 of HLA-DRA and HLA-DRBI*0401 genes and by staining of peripheral blood cells using anti-HLA-DR mAb, L243. C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME), and C2D mice were purchased from GenPharm International (Mountain View, CA).
Flow Cytometry Analysis. Spleen cells or thymocytes (5 X 1 (15) were suspended in 100 p~l of RPMI medium containing 2% FCS and 0.1% sodium azide and incubated on ice in the presence of mAb for 30 rain. The cells were washed twice with PBS containing 0.1% sodium azide and 0.1% BSA, and then once with PBS containing 0.1% sodium azide. The cells were analyzed on a FACSort | using LYSIS II software. The following mAbs were used in the experiments: Anti-HLA-DR mAb, L243; anti-B220 mAb, RA3-6B2; anti-CD11[3 mAb, M1/70; anti-IEI3 mAb, 17. Peptide Binding Assay. Peptides were prepared using solid phase synthesis procedures as described (17) . Their sequences are described in Table 1 . MHC class II molecules were purified from Histological Analysis. The paralyzed mice were sacrificed 30 d after primary challenge. The spinal cords and brains were removed and fixed in 10% phosphate-buffered formalin. The paraffinembedded sections were stained with hematoxylin/eosin and examined under light microscopy.
Results

Generation of HLA-DRA-IEaee /HLA-DRB I* O4O I-IEaj8 Tg mice.
We produced Tg mice with chimeric humanmouse MHC class II genes that encode proteins composed of the antigen binding domains from HLA-DRA and HLA-DRBI*0401, and the remaining domains from the IEa-cx and -13 chains. We used IE genes, because HLA-DR. molecules bear more homology to IE than to IA at the amino acid sequence level. The chimeric gene constructs were manipulated by replacing exon 2 of IEa-ot or IEd-]3 genomic DNA with gene fragments containing exon 2 of HLA-DRA or HLA-DRB 1"0401 respectively, as described in Materials and Methods. Tg mice produced by comicroinjection with the two gene constructs were backcrossed to MHC class II deficient (IAI3-,IEex-) mice (19) . As shown in Fig. 1 A, B220 + cells brighdy expressed the chimeric MHC class II molecules, while CDllb + cells expressed them dimly. This expression pattern was the same as that of routine MHC class II genes (data not shown), indicating that the transgenes were expressed in a regular, tissue-specific manner. Since it has been reported that endogenous IE T Cell Development in Tg Mice. It has been shown that mature, MHC class II-restricted CD4 + T cells do not develop in MHC class II-deficient mice (19, 21) . This evidence suggests that the expression of MHC class II molecules closely influences the development of CD4 + T cells in the thymus. Thus, we examined whether mouse T cells could develop properly in a human-mouse MHC class II environment. As shown in Fig. 2 , CD4 § T cells developed normally in the thymus and spleen of both Tg (IA-,IE-) mice and their non-Tg (IAb+,IE -) littermates. We next examined the development of T cell repertoire in Tg (IA-,IE-) mice and found that T cells expressing V135-, V[311-, or VI312-TCR gene segments were specifically deleted. In contrast, V]36 + and V1310 + T cells were significantly increased in the spleen of Tg mice (Fig. 3) .
Antigen-binding Specificity of HLA-DRB I* O4O I-IE Molecules.
Since antigens bind to the first domain of MHC class II molecules, we expected similar antigen-binding specificity between HLA-DRBI*0401-IE and HLA-DRBI*0401 molecules. The most crucial residues in the peptide-binding motifofHLA-DRBl*0401 are an aromatic or aliphatic anchor residue at position 1, and a residue with a hydroxyl group at position 6 (22). Peptide ml-7 (YRAMATL) possesses the full binding motif for HLA-DRBI*0401, and thus, binds to HLA-DRBI*0401 with a high affinity (Table 1) (23). We used substitutions at position 6 of ml-7 to compare the binding specificity of the chimeric molecules with that of HLA-DRBI*0401. As shown in Table 1 , amino acid substitutions at position 6 resulted in nearly identical changes in binding affinity for both HLA-DRBI*0401 and HLA-DRBI*0401-IE molecules. Although R6-ml-7 is an apparent exception, we should point out that the SPA peptide binding assay is less sensitive at peptide concentration higher than 10 IxM, and the IC50 values, 3.3 and >10 I.tM, both indicate that the peptides are very poor binders or nonbinders for the respective molecules. Therefore, these results have indicated that the HLA-DRBI*0401-IE molecule mimics the HLA-DRBI*0401 molecule in terms of peptide binding specificity.
T Cell Response to Antigenic Peptides in Tg Mice.
To study the HLA-DRBl*0401-restricted T cell response in Tg mice, Tg and non-Tg mice were immunized with HA307-319 or HA-R6. As shown in Table 1 , HA307-319 is a good binder to both DRBI*0401 and DRBI*0401-IE, while HA-R6, a peptide with Arg substituted at position 314 of HA307-319 is nearly a non-binder. Immunization of Tg mice with HA307-319 elicited T cell proliferation, while HA-R6 did not (Fig. 4) . The absence of proliferative response to HA-R6 is most likely due to a low binding affin- ity to HLA-DR_BI*0401-IE molecules since an Arg residue at relative position 6 of the binding motif is not tolerated (see in Table 1 ). The T cell proliferation to HA307-319 was inhibited by the anti-HLA-DP,, mAb, LB3.1. Immunization ofnon-Tg mice with HA307-319 failed to elicit any T cell proliferation (Fig. 4) . These results indicate that the T cell proliferation was HLA-D1L-restricted, i.e., the HLA-DRA-IEodHLA-DRBI*0401-IE[3 molecules present antigens effectively to T cells in the Tg mice.
Development of EAE in Tg Mice Immunized with PLP175-192 or MBP87-106. The major imanunodominant epitopes
of MBP are residues 87-106 and 143-168 for individuals with HLA-DR4 alleles. Based on the peptide-binding motif of HLA-DRBI*0401 (22) and peptide-binding results using overlapping 20--amino acid peptides of PLP (12) ~, we assumed that PLP175-192 could be an immunodominant epitope for HLA-DR4 individuals. As we expected, PLP175-192 binds HLA-DRBI*0401 as strongly as MBP87-106 (Table 1). The amino acid sequences of PLP175-192 and MBP87-106 are identical between human and mouse, and thus, they represent autoantigens for both species. We therefore examined the T cell proliferative responses with these peptides. As shown in Fig. 5 A, lymph node ceils from SJL/J mice immunized with MBP87-106 proliferated in response to the antigen, while little or no proliferative response was detected in Tg mice immunized with MBP87-106. In contrast, immunization with PLP175-192 provoked a strong T cell response to this peptide in Tg mice (Fig. 5/3 ). T cell response to PLP175-192 was inhibited by both anti-DRot mAb, LB3.1, and anti-HLA-DP,[3 mAb, 1-1C4 (24, 25) , but not by anti-IEl3 mAb, 17.3.3 ( Fig. 5/3 ). This result indicated that T cell proliferation to PLP175- ,. 9 .. 192 was restricted by the transgenic class II molecule 9 We then tested the development of EAE by immunizing with PLP175-192 or MBP87-106. As shown in Table 2 and Fig. 6 , Tg mice immunized with PLP175-192 showed signs of EAE 14-17 d after primary immunization. Most of the mice immunized with PLP175-192 showed a progression of symptoms beginning with tail atony, followed by hind-limb paralysis, weakening of the forelimbs and eventually death (Fig. 6 ). In contrast, Tg mice immunized with MBP87-106 developed only a mild EAE. To examine that EAE was induced by DR4-restricted T cells, we used non-Tg/IA-,IEmice as a negative control. The mice did not develop the disease, thus the EAE development was mediated by DR4-IE chimeric molecules. Histological studies of the spinal cord and brain from the paralyzed Tg mice revealed numerous inflammatory foci in white matter, and demyelination and axonal degeneration of nerves were observed in the spinal cord (Fig. 7) . The results have indicated that HLA-DRAIEc~/HLA-DRBI*0401-IE~3 Tg mice are susceptible to EAE, and that PLP175-192 is a more potent encephalitogenic epitope than MBP87-106 in these mice.
Discussion
To study the development of HLA-DR4-1inked autoimmune diseases, we generated transgenic mice possessing HLA-DR4-IE chimeric MHC class II genes, because it was unclear whether the murine CD4 molecule could be activated by HLA-DR4 molecules as effectively as it could be by mouse MHC class II molecules. Although it has been reported that murine CD4 interacts well with HLA-DR1 molecules (26) ,this cannot be extrapolated directly to HLA-DR4 molecules, since human CD4 does not interact equally well with all HLA-DR allotypes (27) . Additionally, the cytoplasmic tail of MHC class II molecules plays an important role in T cell activation and in the recycling of MHC class II molecules (28) . Signal transduction from the cytoplasmic tail regulates the development of Thl/Th2 T helper cells through the activation of B7 molecules (29) , and this signal might be critical for the development of autoimmune diseases. Thus, human/mouse chimeric class II gene constructs appeared to be a better choice than fi.fll HLA-DR genes for production of HLA-DR Tg mice. However, we could not completely rule out the possibility that the joining of human first domains to murine second domains would produce an altered conformation of the human antigen binding site. Thus, we compared the antigen-binding specificity of HLA-DRBI*0401 and HLA-DRBI*0401-IE molecules, respectively. The specificity and affinity of antigen-binding by these molecules were very similar (Table 1) . We also examined the peptide-binding specificity of another chimeric molecule we constructed, HLA-DRBI*0404-IE molecules. The peptide-binding specificity to HLA-DRBI*0404-IE molecules showed the same specificity to HLA-DRB1*0404 molecules (unpublished observation). These results indicated that HLA-DR4-IE molecules could substitute the HLA-DR4 molecules with respect to first domain-dependent functions in Tg mice. As shown in Fig. 4 and previous reports (1, 2), HA307-319 specific DR4-restricted T cells were elicited to proliferate in Tg mice after immunization with the peptide. We next examined whether HA307-319-specific human T cell clones could be activated by the peptide presented by HLA-DR4-IE chimeric molecules. Although the clones were activated by HA307-319 presented by native DR4 molecules expressed on murine fibroblast cells, they were barely activated by the same peptide presented on splenocytes from Tg mice (data not shown). This suggested that the association of human CD4 molecules with the chimeric class II was insufficient to activate these T cells.
To eliminate any influence of endogenous MHC class II on the development of autoimmune disease, the HLA-DR4-IE Tg mice were backcrossed to MHC class II-deficient (IA~-,IEot-) mice. Endogenous IE[3 associated with HLA-DRA-IE0t was not detected by FACS | analysis in certain Tg mouse lines (see in Fig. 1 B) . Mice which express IE[3 have low copy number of transgene (1-10 copies), while IE[3-non-expressing mice have high copy number (70-120 copies). Thus, the difference in expression might be due to either a dilution of mixed DRA-IEo#IE As shown in Table 1 and Fig. 5 A, although SJL mice developed a proliferative T cell response to MBP87-106, a response was barely detectable in Tg mice in spite of the binding of MBP87-106 to DRBI*0401-IE molecules. A possible explanation for this discrepancy is that the thymic positive selection for MBP87-106-specific T cells is different between SJL and Tg mice because of their different M H C class I1 haplotypes. However, since MBP87-106 reactive T cells have been isolated from HLA-DRBI*0401 humans, it is more likely that the relevant specificity is missing from the T C R repertoire of Tg mice. This may be due to the limited homology of T C R genes between human and mouse (32) , or the deletion of certain T cell subsets by endogenous M M T V integrants. Similar results were observed in SJL-TCR V[38.2 Tg mice, which had a limited T cell repertoire because ofallelic exclusion by the transgene (33) . In these mice, immunization with a PLP peptide elicited a strong T cell proliferation, while immunization with MBP87-106 barely stimulated T cells. The result suggests that the TCI~ diversity of MBP87-106-reactive T cells is more limited than that of PLP175-192-specific T cells. The same explanation may apply to the minimally-detectable T cell response to MBP87-106 in our D R 4 -I E Tg mice. The fact that these Tg mice developed mild EAE when immunized with MBP87-106 suggests that a small population of encephalitogenic MBP87-106 specific T cells does exist. However this T cell population may be too small to be detected in the primary T cell proliferation assay.
Herein The results also demonstrate that a human M H C class II binding site alone can confer susceptibility to autoimmune disease. The Tg mice reported here will be useful to study autoantigens involved in the development o f other autoimmune diseases associated with the HLA-DRBI*0401 allele.
